Cellyan Biotechnology Co., Ltd (HKPD)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | - | - | - | 13 | 17 | 20 | 13 | - |
| Operating profit | $m | 0 | -1 | ||||||
| Net profit | $m | - | - | - | 1 | 1 | -0 | -1 | - |
| EPS reported | $ | -0.00 | -0.02 | ||||||
| Operating cashflow per share | $ | 0.06 | -0.04 | ||||||
| Capex per share | $ | 0.02 | 0.01 | ||||||
| FCF per share | $ | 0.05 | -0.04 | ||||||
| Free cash flow | $m | 0 | -1 | ||||||
| Net debt | $m | -1 | 1 | ||||||
| Book value equity | $m | 5 | 10 | ||||||
| Book value per share | $ | 0.49 | 0.27 | ||||||
| Number of shares | m | 10.21 | 36 | ||||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | 1.95 | 1.02 | ||||||
| P/S LTM | x | 0.48 | 0.73 | ||||||
| P/FCF LTM | x | 23.52 | -12.38 | ||||||
| EV/EBITDA LTM | x | 9.42 | -12.38 | ||||||
| EV/Sales LTM | x | 0.56 | 0.41 | ||||||
| Earnings Yield LTM | % | -0.28% | -15.19% | ||||||
| FCF Yield | % | +4.25% | -8.08% | ||||||
| Quality | |||||||||
| ROE | % | -0.54% | -13.85% | ||||||
| ROIC | % | -1.34% | -8.91% | ||||||
| Operating margin | % | +0.65% | -4.04% | ||||||
| Gross margin | % | +11.89% | +8.80% | ||||||
| FCF/Sales | % | +2.04% | -3.01% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +21.72% | -19.50% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | -91.79% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 0.17 | -0.63 | ||||||
| Net Debt/EBITDA | x | 1.35 | -3.89 | ||||||
| EBIT/Net interest | x | 1.35 | -13.84 | ||||||
| Net debt/market cap | % | +19.25% | +36.66% | ||||||
| Net debt/Equity | x | -0.23 | 0.07 | ||||||
| Gross debt/equity | x | 0.48 | 0.13 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cellyan Biotechnology Co., Ltd (HKPD)
No price history available.
Not enough data to calculate KvantraRank
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Cellyan Biotechnology Co., Ltd, an investment holding entity, primarily operates within the over-the-counter (OTC) pharmaceutical sector, serving markets across Hong Kong and mainland China. The company's services encompass the international sourcing and distribution of OTC medications, alongside comprehensive e-commerce supply chain management. Furthermore, it provides essential logistical support, including customs clearance, drug registration, and warehousing facilities. Cellyan Biotechnology caters to a diverse clientele, which includes logistics partners for e-commerce platforms, various merchants, and pharmaceutical distributors. Founded in 2023, the company is based in Yau Tong, Hong Kong. It was formerly known as Hong Kong Pharma Digital Technology Holdings Limited and officially adopted the name Cellyan Biotechnology Co., Ltd in December 2025.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free